Gossamer Bio to Participate in Upcoming Investor Conferences
News > Health News
Audio By Carbonatix
6:31 AM on Friday, November 7
The Associated Press
SAN DIEGO--(BUSINESS WIRE)--Nov 7, 2025--
Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will participate in the following investor conferences in November.
UBS Global Healthcare Conference | ||
Date / Time: | November 10 th | |
Format: | 1x1’s | |
Location: | Palm Beach, FL |
Guggenheim Securities Healthcare Innovation Conference | ||
Date / Time: | November 11 th, at 10:00 AM ET | |
Format: | Presentation & 1x1’s | |
Location: | Boston, MA | |
Webcast Link: |
About Gossamer Bio
Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with pulmonary hypertension.
View source version on businesswire.com:https://www.businesswire.com/news/home/20251107017321/en/
CONTACT: For Investors and Media
Bryan Giraudo, Chief Financial Officer & Chief Operating Officer
Gossamer Bio Investor Relations
KEYWORD: MASSACHUSETTS CALIFORNIA FLORIDA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH SCIENCE PHARMACEUTICAL RESEARCH
SOURCE: Gossamer Bio, Inc.
Copyright Business Wire 2025.
PUB: 11/07/2025 07:31 AM/DISC: 11/07/2025 07:31 AM
http://www.businesswire.com/news/home/20251107017321/en
